SEC Form 4 · accession 0000899243-17-008436
MyoKardia Inc · MYOK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anastasios Gianakakos
Officer — President and CEO · Director
Period of report
Mar 20, 2017
Accepted (ET)
Mar 22, 2017 · 8:39 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001552451
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 20, 2017 | M | 1,200 | $1.51 | A | 509,454 | D | |
| Common Stock | Mar 20, 2017 | S | 1,412 | $15.00 | D | 508,042 | D | |
| Common Stock | holding | — | — | — | 181,169 | I | By Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $1.51 | Mar 20, 2017 | M | 1,200 | D | — | Jun 3, 2025 | Common Stock | 1,200 | 206,962 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F225% of the shares subject to this option vested and became exercisable on June 4, 2016, and the remaining shares subject to this option shall vest and become exercisable in 36 equal monthly installments thereafter.